|Bid||78.55 x 800|
|Ask||82.46 x 1000|
|Day's Range||80.33 - 83.68|
|52 Week Range||74.31 - 129.59|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.10|
MannKind Corp (MNKD) reported financial results for their second quarter ending June 30th and provided a business update. Both gross and net product sales set new records, as did product margin. As a reminder, Afrezza is sold in 4-,8- and 12-unit cartridges.
NEW YORK, Aug. 19, 2019 -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a.
Martine Rothblatt became the CEO of United Therapeutics Corporation (NASDAQ:UTHR) in 2016. First, this article will...
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 6, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive ...
United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.
Martine Rothblatt is advancing her plan to triple United Therapeutics Corp.’s business over the next few years.
United Therapeutics (UTHR) delivered earnings and revenue surprises of 51.25% and 12.60%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2019. ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2019 financial ...
While small-cap stocks, such as United Therapeutics Corporation (NASDAQ:UTHR) with its market cap of US$3.3b, are...
The judge’s decision came after more than an hour and a half of discussion in a cavernous courtroom.
The recent weakness in United Therapeutics stock is attributable to concerns over generic competition for its pulmonary arterial hypertension drug Remodulin and shareholder base churn, Auster said in the Monday upgrade note.
Shares of the biotech firm United Therapeutics rose after Credit Suisse said the recent cratering of the stock’s price was undeserved.
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
The merger comes while a subsidiary is expanding in Jacksonville and possibly pursuing city incentives.